Analytical Data
-
基因名
C-MPL
-
简介
C-MPL protein is a key member of the type I cytokine receptor family and is essential for mediating cellular responses to various cytokines. Its research enhances our understanding of cell signaling, providing potential applications for therapeutic intervention in hematopoietic disorders and immune disorders. C-MPL Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C-MPL protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
别名
TPO-R; CD110; MPL; c-Mpl; MPLV; K12
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A2K5UGC7
-
表达区间
Q22-T489
-
蛋白长度
Extracellular Domain
-
分子量
60-70 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C-MPL, or c-Mpl, is a critical receptor for thrombopoietin (TPO), a key hormone in the regulation of megakaryocyte and platelet production. Understanding the structure and function of C-MPL is imperative for addressing various hematological disorders, including thrombocytopenia and other platelet-related diseases. Dysregulation of the C-MPL signaling pathway can result in severe conditions, such as myeloproliferative neoplasms or other forms of leukemia. Recent advances in recombinant protein technology have facilitated the production of C-MPL, allowing researchers to study its molecular mechanisms and interactions in detail. By generating recombinant C-MPL proteins, scientists can investigate their role in TPO signaling, receptor dimerization, and downstream signaling cascades. These studies provide insights into how C-MPL operates at the cellular level, paving the way for the development of therapeutic interventions targeting this receptor. Furthermore, recombinant C-MPL can be utilized for the development of diagnostic tools or therapeutic agents, enhancing our understanding of platelet physiology and pathology. As research progresses, the implications of C-MPL in clinical settings continue to expand, underscoring its significance in both basic and translational research.
